GW Pharmaceuticals PLC just released its latest quarterly financial results, posting adjusted earnings of -$3.12 per share and revenues of $3.35 million.
Currently, GWPH is a Zacks Rank #2 (Buy), but that could change based on today’s results. Shares of the company have gained about 27% over the past month but dropped slightly during regular trading hours today.
The stock is currently up 1.3% to $146.48 per share in after-hours trading shortly after its earnings report was released.
GW Pharmaceuticals:
Missed earnings estimates. The company posted an adjusted loss of $3.12 per share, missing the Zacks Consensus Estimate of $2.22 per share loss. Investors should note that this consensus projection has trended downward over the duration of the quarter.
Beat revenue estimates. The company saw revenue figures of $3.35 million, topping our consensus estimate of $2.0 million. Total revenue was up 64.2% on a year-over-year basis.
“The positive outcome of the Epidiolex FDA Advisory Committee meeting was a momentous event for GW. The strength and consistency of the clinical data, together with the public presentations that featured very moving personal stories of the challenges associated with managing these difficult forms of epilepsy, led to a unanimous vote in support of approval,” said CEO Justin Gover.
Here’s a graph that looks at GWPH’s recent price performance:
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain.
Check back later for our full analysis on GWPH’s earnings report!
Want more market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Image: Bigstock
GW Pharmaceuticals (GWPH) Stock Moving Higher After Posting Q2 Earnings
GW Pharmaceuticals PLC just released its latest quarterly financial results, posting adjusted earnings of -$3.12 per share and revenues of $3.35 million.
Currently, GWPH is a Zacks Rank #2 (Buy), but that could change based on today’s results. Shares of the company have gained about 27% over the past month but dropped slightly during regular trading hours today.
The stock is currently up 1.3% to $146.48 per share in after-hours trading shortly after its earnings report was released.
GW Pharmaceuticals:
Missed earnings estimates. The company posted an adjusted loss of $3.12 per share, missing the Zacks Consensus Estimate of $2.22 per share loss. Investors should note that this consensus projection has trended downward over the duration of the quarter.
Beat revenue estimates. The company saw revenue figures of $3.35 million, topping our consensus estimate of $2.0 million. Total revenue was up 64.2% on a year-over-year basis.
“The positive outcome of the Epidiolex FDA Advisory Committee meeting was a momentous event for GW. The strength and consistency of the clinical data, together with the public presentations that featured very moving personal stories of the challenges associated with managing these difficult forms of epilepsy, led to a unanimous vote in support of approval,” said CEO Justin Gover.
Here’s a graph that looks at GWPH’s recent price performance:
GW Pharmaceuticals PLC Price and Consensus
GW Pharmaceuticals PLC Price and Consensus | GW Pharmaceuticals PLC Quote
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain.
Check back later for our full analysis on GWPH’s earnings report!
Want more market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>